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INTRODUCTION 
A literature search was conducted to identify 
publications addressing the honeymoon phase 
in children with Type 1 diabetes mellitus (T1DM). 
Medline, EMBASE, and Ovid were searched using 
the following search terms: ‘clinical remission’, 
‘partial remission’, ‘partial clinical remission’, 
‘honeymoon phase’, ‘C-peptide’, ‘type 1 
diabetes’, ‘children’, ‘pediatric type 1 diabetes’, 
Abstract
The honeymoon phase, or partial clinical remission (PCR) phase, of Type 1 diabetes mellitus (T1DM) is 
a transitory period that is marked by endogenous insulin production by surviving β cells following a 
diabetes diagnosis and the introduction of insulin therapy. It is a critical window in the course of the 
disease that has short and long-term implications for the patient, such as a significant reduction in 
the risk of long-term complications of T1DM. To promote long-term cardiovascular health in children 
with newly diagnosed T1DM, three key steps are necessary: the generation of a predictive model for 
non-remission, the adoption of a user-friendly monitoring tool for remission and non-remission, and 
the establishment of the magnitude of the early-phase cardiovascular disease risk in these children 
in objective terms through changes in lipid profile. However, only about 50% of children diagnosed 
with T1DM experience the honeymoon phase. Accurate and prompt detection of the honeymoon 
phase has been hampered by the lack of an objective and easily applicable predictive model for 
its detection at the time of T1DM diagnosis, the complex formulas needed to confirm and monitor 
PCR, and the absence of a straightforward, user-friendly tool for monitoring PCR. This literature 
review discusses the most up-to-date information in this field by describing an objective predictive 
model for non-remission, an easy tool for monitoring remission or non-remission, and objective 
evidence for the cardiovascular protective effect of PCR in the early phase of the disease. The goal is to 
present non-remission as an independent clinical entity with significantly poorer long-term prognosis 
than partial remission.
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and‘paediatrics type 1 diabetes’. Nine papers 
were excluded because they featured an unclear 
definition of partial clinical remission.
OVERVIEW AND DEFINITION  
OF PARTIAL CLINICAL REMISSION  
IN CHILDREN WITH TYPE 1  
DIABETES MELLITUS
A key limitation of the early management of 
T1DM is the lack of a uniform strategy to prevent 
early dysglycaemia in non-remitters; these are 
children and adolescents who fail to experience 
the honeymoon phase or the partial clinical 
remission (PCR) phase of the disease.1-4 T1DM is 
a disorder of persistent hyperglycaemia resulting 
from autoimmune destruction of the pancreatic β 
cells.5,6 PCR often follows the diagnosis of T1DM and 
this phase is marked by an increased functionality 
of the surviving β cells with increased endogenous 
insulin production.4,7 PCR typically lasts 3–12 
months;8 however, recent studies have shown 
evidence for C-peptide production and thus 
residual β cell function at >5 years following the 
diagnosis of T1DM.9 C-peptide is cosecreted with 
insulin from pancreatic β cells and represents 
a surrogate marker of residual β cell function. 
In physiologic concentrations, C-peptide acts 
to improve both microvascular blood flow and 
microvascular endothelial function through the 
release of endothelial nitric oxide.10 Following 
the diagnosis of T1DM, serum C-peptide 
concentration undergoes an initial exponential 
fall followed by a stable phase of decline that can 
last for several years.9 The presence of residual 
endogenous insulin secretion in patients with 
T1DM has been linked to a reduced risk of severe 
hypoglycaemia,11,12 development of diabetic 
retinopathy,13 increases in statural growth in 
prepubescent children,14 and improvement in 
long-term glycaemic control.2,15 These findings 
have been recently corroborated by a longitudinal 
study that reported a significantly reduced risk 
for chronic microvascular complications at 7-year 
follow-up in young adults who experienced PCR.2 
Though remitters have an overall long-term 
prognostic advantage over non-remitters, this 
dichotomy is rarely taken into consideration 
during the early phase of diabetes management, 
as there is no specified strategy to prevent early 
dysglycaemia in non-remitters, which represents 
a key limitation of the early management T1DM 
in children.1-4 Research in this field has primarily 
focussed on prolonging the duration of PCR 
in remitters. A review of these studies showed 
differing conclusions because of the severe side 
effect profile of some of the agents,16-20 insufficient 
doses of other experimental agents,21,22 and, 
more importantly, the non-standardisation of 
insulin regimens16,17,21,22 during these interventions, 
which confounded the effect of the experimental 
agents. The immunomodulatory approach 
is promising, but the regimens tested lack 
sufficient benefit to justify the risk.16,17 Autologous 
haematopoietic stem cell transplantation,19 an 
approach that halts autoimmune destruction 
of targeted tissue and re-establishes tolerance, 
has huge potential in carefully selected patients, 
in whom it has resulted in remission for >3.5 
years in the best cases. However, its effect is 
predicated on the existence of functional β cells 
and so would not be effective in non-remitters.23 
More importantly, its numerous side effects, 
including alopecia, febrile neutropenia, nausea, 
de novo autoimmunity, infections, and death,20 
have limited its widespread acceptance. Vitamin 
D supplementation, on the other hand, is safe 
and may slow T1DM progression,21,22 but existing 
studies have caveats that prevent widespread 
implementation of this recommendation. There 
is an ongoing randomised control trial evaluating 
the effect of moderately high-dose vitamin D 
supplementation on the duration of PCR; its 
results will be published in 2021.24 It is therefore 
crucial to understand the unique disadvantages 
of non-remitters to ensure that they are protected 
from early-phase metabolic derangements and 
the attendant long-term complications of T1DM.
Prevalence of Non-Remission in 
Children with Type 1 Diabetes Mellitus
The introduction of the gold-standard definition 
for PCR, the insulin dose-adjusted HbA1c 
(IDAA1c), in 2009 allowed for a consensus 
on the estimation of PCR.8 Based on recent 
studies, the prevalence of PCR in children and 
adolescents is approximately 50%.2,4,25,26 This 
means that a significant proportion of children 
and adolescents diagnosed with T1DM will not 
experience PCR.1,27-29 
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Mechanisms of Non-Remission 
The molecular mechanisms underlying remission 
or non-remission are not fully characterised; 
however, certain factors play key roles, including 
increased β cell strain,30 unfavourable cytokine 
profile,31 increased glucagon concentration,32 
and the role of immune mediators and genetic 
markers. Increased β cell strain is marked by poor 
processing of proinsulin because it has been 
shown that overweight male children who are 
more likely to undergo remission have improved 
processing of proinsulin.30 In addition, remitters 
are reported to possess a distinctive cytokine 
profile with a less damaging effect on the β 
cells.31 Remitters also have a lower glucagon 
concentration, a finding that is consistent 
with the premise that glucagon production is 
suppressed by intra-islet insulin production 
and release.32 A study suggesting a key role 
of immune mechanisms in PCR33 reported 
significantly lower concentrations of IFN-γ 
in remitters compared to non-remitters and 
controls. A higher frequency of CD4+ CD25+ 
CD127hi cells, a non-regulatory T cell subset of 
memory T cells, correlated with a slower rate of 
T1DM progression,34,35 supporting the hypothesis 
of a protective role for immune mediators for 
PCR. Moya et al.35 reported that a combination 
of the frequency of the CD4+ CD25+ CD127hi cells 
with glycaemic markers at the time of diagnosis 
of T1DM could serve as a predictor of the 
duration of PCR. A similar study reported that the 
highest levels of apoptosis of CD4+ CD25+hi T cells 
are seen in subjects with either new-onset T1DM 
or those with an increased number of diabetes-
associated autoantibodies.36 Another study 
found that an increase in islet antigen-specific 
IL-10-producing cells in subjects with new-onset 
T1DM correlated with improved glycaemic control, 
while increased FoxP3 expression in similar 
subjects predicted a worse outcome.37 A genetic 
study38 reported that the level of circulating 
microRNA, has-miR-197-3p, at 3 months following 
the diagnosis of T1DM was a strong predictor of 
residual β cell function 1 year after the diagnosis 
of the disease. Thus, a constellation of genetic, 
immune, hormonal, and inflammatory factors 
predicts the occurrence and the duration of 
remission or non-remission.
The Shortcomings of the Singular 
Focus on the Determinants of 
Remission at the Expense  
of Non-Remission 
The decision to focus this review on the 
determinants of clinical non-remission was 
predicated on the urgent need for a paradigm 
shift in the approach to the management 
of children with new-onset T1DM. A clear 
characterisation of non-remission as an entity 
would enable clinicians to institute measures 
to ensure optimal glycaemic control very early 
in the course of the disease in non-remitters,3 
thus preventing early dysglycaemia. This new 
approach, which is based on the predictive 
model for non-remission, will have a significant 
impact on diabetes complications given the high 
prevalence of non-remission (>50%) in both 
paediatric and adult patients.1,27,29,39 A predictive 
model would also enhance candidate selection 
for β cell preservation trials, as well as in trials 
focussed on the prodromal phase of T1DM, such 
as the Type 1 Diabetes TrialNet Study.40 
A recent study of 204 children and adolescents 
<18 years of age with new-onset T1DM 
examined the prevalence and key indicators of 
non-remission and reported a prevalence rate 
of non-remission of 57.8%.41 This study further 
demonstrated that the principal predictors of 
non-remission in this population were serum 
bicarbonate <15 mg/dL, younger age at 
diagnosis, increasing number of diabetes-
associated autoantibodies, and female sex.41 In 
contrast, male sex and older age were associated 
with decreased risk of non-remission. One 
study reported that remission occurred more 
frequently in younger patients;42 however, other 
published studies reported otherwise.4,8,25,41,43-45 
Serum 25-hydroxyvitamin D did not affect 
the risk of non-remission. This study further 
quantified the glycaemic cost of non-remission by 
demonstrating a prolonged period of a 
significantly elevated HbA1c level of 3–18 months 
post-diagnosis in non-remitters compared to 
remitters25 (Figure 1). 
MONITORING OF REMISSION  
AND NON-REMISSION
Despite the adoption of IDAA1c as the gold-
standard marker for PCR, there is no consensus 
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on a simple and user-friendly tool for the 
detection and monitoring of PCR in children 
and adolescents.4,26,41 This has limited the 
application of IDAA1c as a universal tool for the 
monitoring of PCR in children with new-onset 
T1DM. Therefore, the next challenge in preventing 
early-phase dysglycaemia in children with T1DM 
was to develop a simple, user-friendly tool for 
the monitoring of both remission or non-remission 
to ensure the institution and maintenance of 
intensive glycaemic control in these patients, 
especially the non-remitters who lack the 
honeymoon-associated endogenous protection 
from early dysglycaemia and the attendant 
long-term complications.1,11-13,27-29,46 
The Drawbacks of the Gold Standard 
Marker for the Detection of Partial 
Clinical Remission: Insulin  
Dose-Adjusted HbA1c 
The IDAA1c formula is expressed as HbA1c (%) 
+ (4 x total daily dose of insulin [TDDI] [units/
kg/24 hours]). This formula, which integrates 
both HbA1c and TDDI, has been validated in 
multiple cohort studies;4,7 however, this surrogate 
marker of serum C-peptide concentration has 
been criticised for its numerous shortcomings.4 
The first major drawback is that age, which is a 
principal determinant of PCR, is not included in 
the formula.8 Secondly, IDAA1c underestimates 
PCR in younger children who often have 
lower serum C-peptide concentrations given 
their smaller pancreatic β cell mass, as the 
formula for IDAA1c was derived using a higher 
C-peptide cut-off value of 300 pmol/L, instead 
of the 200 pmol/L validated by the Diabetes 
Control and Complications Trial.3,8 Thirdly, 
IDAA1c underestimates PCR frequency in older, 
overweight European females with insulin 
resistance,4 as IDAA1c is unable to discriminate 
between insulin sensitivity and insulin secretion.4 
IDAA1c also has poor sensitivity for the risk of 
hypoglycaemia in patients with newly diagnosed 
T1DM3 and the multistep approach to the 
calculation of IDAA1c represents a major barrier 
to its adoption by busy clinicians, which limits 
its widespread use in endocrine clinics. The final 
shortcoming of this formula is that IDAA1c 
may not be generalised to all children with 
T1DM because it was derived from a cohort of 
European and Japanese subjects, who have 
markedly different diabetes characteristics 
from the general population of the USA.3,47 
Poor generalisation of the IDAA1c was recently 
demonstrated in the USA in a retrospective study 
that used IDAA1c to compare the glycaemic 
and cardiovascular parameters of 80 African-
American, 216 Hispanic, and 631 non-Hispanic 
white (NHW) youths <19 years old with T1DM.48 
The authors reported that African-American and 
Hispanic youths had higher mean HbA1c and 
BMI, and a lower frequency of remission, compared 
to NHW youths.48 Surprisingly, this study found 
no statistically or clinically significant differences 
in lipid parameters between the groups in the 
first 3 years of disease, despite the persistently 
higher HbA1c in the ethnic minority youths, 
suggesting that IDDA1c underestimated PCR 
in these youths in the USA, similar to the 
underestimation of PCR in obese European 
females.4 In other words, most of the African-
American and Hispanic youths classified as 
non-remitters were false-negatives.47 This 
underestimation of PCR is exacerbated by the 
fact that USA ethnic minority youths with 
T1DM have a mean HbA1c of 0.4% higher 
than NHW youths for the same mean glucose 
concentration.49,50 They also have a more 
rapid rise in HbA1c trajectory from the time of 
diagnosis onwards.51 As a result of these 
shortcomings, there is now a call to design an 
ethnic group-specific IDAA1c value for ethnic 
minorities in the USA,47 and for additional 
research to clarify the usefulness and 
performance of IDAA1c in routine clinical practice.4 
Specifically, there is a need to determine age, 
sex, and demographic-specific IDAA1c limits 
for the definition of PCR based on the serial 
determination of serum C-peptide concentration 
to ensure that the false-negative rate from the 
current criterion is reduced and that all remitters 
are accurately identified.4,47,52,53
The Comparison of Insulin Dose-
Adjusted HbA1c to Other Markers  
of Partial Clinical Remission
A comparison of the IDAA1c to earlier 
definitions of PCR,26-30,47,54,55 such as HbA1c ≤7.5%, 
TDDI ≤0.5 units/kg/day,54 or combinations of 
the parameters, such as HbA1c ≤7.5% and TDDI 
≤0.5 units/kg/day,55 showed that while IDAA1c has 
a stronger correlation with stimulated C-peptide 
concentration than previous definitions,8 IDAA1c 
is less sensitive than TDDI <0.5 units/kg/day for 
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early detection of PCR, but is more specific for 
the detection of PCR between 6 and 12 months.8 
Furthermore, the use of either TDDI ≤0.5 units/
kg/day or HbA1c <7.5% in isolation was found 
to overestimate the prevalence of PCR, 
although the use of a combination of TDDI ≤0.5 
units/kg/day and HbA1c <7.5% underestimated 
PCR.8 Recently, a Belgian group, citing the 
above shortcomings of the IDAA1c, developed 
a new tool for the detection of PCR called the 
glycaemic target-adjusted HbA1c,26 which has a 
sensitivity of 72% to detect PCR based on the 
IDAA1c definition.
Given the drawbacks of the IDAA1c and 
the shortcomings of the other definitions, 
a recent study compared IDAA1c to a new, 
straightforward, user-friendly definition of PCR: 
TDDI <0.3 units/kg/day.25,56 This comparison was 
based on the hypothesis that a TDDI <0.3 units/
kg/day could fall in an intermediate position 
between the detection potential of TDDI 
≤0.5 units/kg/day54 and the combination of HbA1c 
<7.5% and TDDI ≤0.5 units/kg/day.55 The rationale 
for this investigation was that endocrinologists, 
who routinely calculate TDDI during regular clinic 
visits, would find the application of TDDI <0.3 
units/kg/day more practical and user-friendly 
for early detection and monitoring of either 
remission or non-remission than the IDAA1c, 
which would ensure a greater acceptance by 
clinicians. The results of this study, which was 
conducted in a USA population, showed that 
TDDI <0.3 units/kg/day and IDAA1c ≤9 identified 
a similar proportion of patients entering PCR: 
40.2% versus 42.2%, respectively, with both 
criteria showing peak prevalence of remission 
at 6–12 months and a similar longitudinal HbA1c 
pattern in the first 3 years of disease (Figure 1). 
Specifically, Figure 1 shows that when PCR was 
defined by IDAA1c ≤9 criterion, mean HbA1c 
was similar at diagnosis between the remitters 
and non-remitters; thereafter, HbA1c became 
significantly lower in the remitters from 3–18 
months and remained non-significantly lower in 
the remitters thereafter. When PCR was defined 
by TDDI <0.3 units/kg/day, HbA1c level appeared 
significantly lower in the remitters at diagnosis 
and at 3 months, and then became non-
significantly lower in the remitters until Month 
15, when the mean HbA1c values became similar 
between the groups. This study concluded that, in a 
head-to-head comparison, the criterion TDDI <0.3 
units/kg/day was noninferior to IDAA1c, as both 
criteria showed similar sensitivity and specificity 
for the detection of PCR in children. However, 
TDDI <0.3 units/kg/day had the advantage 
of being a readily accessible tool for prompt 
detection and monitoring of PCR in a busy clinic 
setting. Therefore, the adoption of the routine 
application of TDDI <0.3 units/kg/day in clinical 
practice should improve the surveillance for 
both remission and non-remission to ensure the 
maintenance of euglycaemia in children requiring 
insulin doses >0.3 units/kg/day.25  
CLINICAL CONSEQUENCE  
OF NON-REMISSION
The next challenge in the characterisation of 
PCR in children and adolescents is to provide 
objective proof of the deleterious cardiovascular 
effects of non-remission in the early phase 
of T1DM, specifically within the first 5 years. 
Such a demonstration could provide the basis 
for recommendations for early detection and 
monitoring of PCR in children to prevent the 
long-term microvascular and macrovascular 
complications that begin in the first few years 
of disease.57 This is particularly important 
because early changes in lipid profile between 
remitters and non-remitters have not been 
previously reported.52
Pathobiology of Early-Phase 
Dyslipidaemia in Children with Type 
1 Diabetes Mellitus: The Need to 
Stratify Patients by Partial Clinical 
Remission History in the Investigation 
of Differences in Lipid Profile
Despite the report by the Diabetes Control 
and Complications Trial of a protective role 
of C-peptide on vasculature in remitters,15 
there have been no data on the characterisation 
of early-phase dyslipidaemia in remitters and 
non-remitters until recently.52 A review of the 
current literature on dyslipidaemia in children and 
adolescents with T1DM showed no consensus 
on lipid pattern and it is believed that a lack of 
stratification of subjects by PCR history may 
have confounded these results.58-61 While 
one longitudinal study reported that 25% of 
youths with T1DM have progressive and persistent 
dyslipidaemia and increased arterial stiffness,58 
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another study in children and adolescents 
with poorly controlled T1DM found a positive 
association between increased arterial stiffness 
and total cholesterol, low-density lipoprotein 
(LDL) cholesterol, and HbA1c.59 In contrast, a 
longitudinal retrospective cohort study in a 
similar population with T1DM found that changes 
in HbA1c and BMI z scores had minimal impact on 
LDL cholesterol and non-high-density lipoprotein 
cholesterol.60 Furthermore, whereas some 
studies reported a significant relationship between 
poor glycaemic control and dyslipidaemia 
in T1DM,58,60 others reported an inconsistent 
pattern of correlation of lipids and HbA1c,62 or no 
correlation at all.63 
However, none of the aforementioned studies 
explored the differences in lipid profiles based 
on patients’ remission statuses, except Redondo 
et al.,48 whose findings were confounded by the 
underestimation of PCR by IDAA1c in ethnic 
minority youths.47 The stratification of children 
and adolescents with new-onset T1DM by PCR 
status is of fundamental importance to ensure 
meaningful comparisons between the groups 
to reduce the inconsistencies in lipid outcomes, 
especially LDL cholesterol concentration, in 
previous studies.58-61 For instance, it is possible 
that the study that reported progressive and 
persistent dyslipidaemia58 could have contained 
a higher proportion of non-remitters, while 
the study that reported only a modest effect of 
HbA1c and BMI on lipid parameters60 might have 
had a higher proportion of remitters. The fact 
that non-remitters make up >50% of children 
and adolescents with new-onset T1DM27,29 makes 
it crucial to stratify subjects based on PCR 
history in all investigations in circulating lipid 
concentrations in patients with T1DM.   
Furthermore, the characterisation of early-phase 
dyslipidaemia in T1DM, specifically the changes 
in LDL cholesterol, based on stratification by 
PCR is imperative because atherosclerosis 
originates in childhood and early adolescence,64,65 
and dyslipidaemia is a primary contributor to 
the increased risk of cardiovascular disease in 
patients with T1DM.64,65 Such an emphasis may 
clarify the possible role of non-remission as a 
non-modifiable risk factor for dyslipidaemia 
in T1DM. 
Figure 1: A longitudinal representation of the patterns of haemoglobin A1c (HbA1c) excursions in remitters and non-
remitters in the first 3 years of diagnosis of Type 1 diabetes mellitus using either insulin dose-adjusted HbA1c ≤9 or 
total daily dose of insulin <0.3 units/kg/day.7,8
IDAA1c: insulin dose-adjusted HbA1c; TDDI: total daily dose of insulin.
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The first step to address this came from a recent 
longitudinal retrospective cohort study of 123 
children and adolescents with T1DM of 5-year 
duration.66 The subjects’ mean age was 11.9±2.9 
years and the cohort consisted of 55 male 
subjects and 68 female subjects. There were 
44 remitters and 79 non-remitters. A timeline 
of 4–5 years after diagnosis was chosen in 
concert with the American Diabetes Association 
(ADA) recommendation to initiate screening 
for diabetes complications in children either 
at the inception of puberty or 4–5 years 
after diagnosis,67 because it was previously 
believed that there was minimal risk of 
dyslipidaemia during the prepubescent years. 
This study excluded children with dyslipidaemia 
or a family history of lipid abnormalities. The 
results showed that children and adolescents 
who experienced PCR had significantly lower 
mean LDL cholesterol 4–5 years after the 
diagnosis of T1DM compared to their peers who 
did not experience PCR52 after controlling for 
age, puberty, glycaemic control, and adiposity. 
The significantly lower LDL in remitters was 
rather striking because a greater proportion 
of the remitters were in puberty 4–5 years 
after the diagnosis of T1DM compared to the 
non-remitters. This is because a previous report 
indicated that pubescent youths with T1DM had 
elevated LDL cholesterol compared to their 
healthy peers,63 and this was attributed to the 
fact that children with T1DM do not show the 
usual pattern of decreasing LDL cholesterol 
during puberty.63 Hence, this study clarified the 
previous report by demonstrating that remitters 
in puberty had similar mean LDL cholesterol 
concentrations as children and adolescents 
without diabetes, a finding that has not been 
previously reported. This report advances 
the field by providing critical and objective 
evidence of early cardiovascular protection by 
PCR. Larger studies are needed to confirm these 
differences in lipid fractions between remitters 
and non-remitters. 
CONCLUSIONS AND SUGGESTED 
CHANGES TO THE LIPID MONITORING 
GUIDELINES OF THE INTERNATIONAL 
SOCIETY FOR PEDIATRIC AND 
ADOLESCENT DIABETES (ISPAD) 
AND THE AMERICAN DIABETES 
ASSOCIATION (ADA) 
This literature review details new developments 
in the clinical application of the honeymoon 
period of T1DM by focussing on non-remission 
as a specific clinical entity with poorer long-
term prognosis than partial remission. The 
author hopes to advance the field by presenting 
strategies to predict and monitor non-remission, 
as well as a justification for the initiation of 
lipid monitoring at the time of diagnosis 
of T1DM in children and adolescents. This 
review has summarised the genetic, immune, 
inflammatory, and biochemical markers that 
could predict remission and non-remission. It 
has also characterised the first clinical predictive 
model dedicated to non-remission in children 
with new-onset T1DM that is based on easily 
obtainable clinical parameters at the time of 
T1DM diagnosis, such as age, sex, BMI, body pH, 
number of diabetes-associated autoantibodies, 
and serum bicarbonate. It further reviewed a 
study showing that a TDDI <0.3 units/kg/day is 
noninferior to the gold standard marker of PCR, 
IDAA1c ≤9. Finally, it reviewed the results of a 
5-year longitudinal study showing evidence for 
early-phase dyslipidaemia in non-remitters who 
had a significantly elevated LDL cholesterol 
level compared to remitters after adjusting for 
confounding variables. Though larger studies 
are needed to confirm these early findings, 
the distinct pattern of the early changes in 
LDL cholesterol in this recent study52 could 
explain the dichotomy in the prevalence of long-
term complications of T1DM between remitters 
and non-remitters.15 Significantly elevated LDL 
cholesterol in non-remitters makes a strong 
case for targeted lipid monitoring in T1DM 
because it suggests that non-remission could be 
a non-modifiable risk factor for cardiovascular 
disease in T1DM. Equally, the early divergence 
in serum LDL cholesterol concentration in these 
paediatric subjects with T1DM supports a 
modification of the current guidelines by 
the International Society for Pediatric and 
Adolescent Diabetes (ISPAD)68 and the ADA67 
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to recommend the initiation of lipid monitoring 
at the time of diagnosis of T1DM regardless 
of the age of the child, in a similar approach 
to the current guidelines for Type 2 diabetes 
mellitus.68 This will ensure an early detection of 
hypercholesterolaemia in non-remitters that 
could be amenable to the institution of early 
therapeutic and dietary interventions coupled 
with ongoing lipid monitoring. 
In conclusion, the adoption of the following 
measures  may serve to improve the long-term 
cardiovascular health of diabetic children 
and adolescents well into adulthood: the 
implementation of a predictive model to detect 
non-remission; using TDDI <0.3 units/kg/day to 
more easily monitor remission or non-remission; 
and the introduction of targeted lipid monitoring 
at the time of diagnosis in all children with 
newly diagnosed T1DM. Larger studies including 
patients of different nationalities are needed to 
confirm the generalisability of these measures.
References
1. Chen YC et al. Clinical characteristics 
of type 1 diabetes mellitus in 
Taiwanese children aged younger 
than 6 years: A single-center 
experience. J Formos Med Assoc. 
2017;116(5):340-4.
2. Niedzwiecki P et al. Influence 
of remission and its duration on 
development of early microvascular 
complications in young adults 
with type 1 diabetes. J Diabetes 
Complications. 2015;29(8):1105-11.
3. Cengiz E et al.; Pediatric Diabetes 
Consortium. Clinical outcomes in 
youth beyond the first year of type 
1 diabetes: Results of the Pediatric 
Diabetes Consortium (PDC) type 1 
diabetes new onset (NeOn) study. 
Pediatr Diabetes. 2017;18(7):566-73.
4. Nagl K et al. Factors contributing to 
partial remission in type 1 diabetes: 
Analysis based on the insulin dose-
adjusted HbA1c in 3657 children 
and adolescents from Germany 
and Austria. Pediatr Diabetes. 
2017;18(6):428-34.
5. Standards of Medical Care in 
Diabetes-2016: Summary of Revisions. 
Diabetes Care. 2016;39 Suppl 1:S4-5.
6. Chmelova H et al. Distinct roles of 
beta-cell mass and function during 
type 1 diabetes onset and remission. 
Diabetes. 2015;64:2148-60.
7. Max Andersen ML et al. Partial 
remission definition: Validation based 
on the insulin dose-adjusted HbA1c 
(IDAA1C) in 129 Danish children with 
new-onset type 1 diabetes. Pediatr 
Diabetes. 2014;15(7):469-76.
8. Mortensen HB et al.; Hvidoere Study 
Group on Childhood Diabetes. New 
definition for the partial remission 
period in children and adolescents 
with type 1 diabetes. Diabetes Care. 
2009;32(8):1384-90.
9. Shields BM et al.; TIGI Consortium. 
C-peptide decline in type 1 diabetes 
has two phases: An initial exponential 
fall and a subsequent stable phase. 
Diabetes Care. 2018;41(7):1486-92.
10. Forst T et al. Role of C-peptide in 
the regulation of microvascular 
blood flow. Exp Diabetes Res. 
2008;2008:176245.
11. Sherry NA et al. Natural history of 
beta-cell function in type 1 diabetes. 
Diabetes. 2005;54 Suppl 2:S32-9.
12. Sorensen JS et al.; Danish Society 
for Diabetes in Childhood and 
Adolescence. Residual beta-cell 
function 3-6 years after onset of 
type 1 diabetes reduces risk of 
severe hypoglycemia in children 
and adolescents. Diabetes Care. 
2013;36:3454-9.
13. Nakanishi K, Watanabe C. Rate 
of beta-cell destruction in type 1 
diabetes influences the development 
of diabetic retinopathy: Protective 
effect of residual beta-cell function 
for more than 10 years. J Clin 
Endocrinol Metab. 2008;93(12):4759-
66.
14. Bizzarri C et al. Residual beta-
cell mass influences growth of 
prepubertal children with type 
1 diabetes. Horm Res Paediatr. 
2013;80(4):287-92.
15. Steffes MW et al. Beta-cell function 
and the development of diabetes-
related complications in the diabetes 
control and complications trial. 
Diabetes Care. 2003;26(3):832-6.
16. Chakhtoura M, Azar ST. The role of 
vitamin D deficiency in the incidence, 
progression, and complications 
of type 1 diabetes mellitus. Int J 
Endocrinol. 2013;2013:148673.
17. van Belle TL et al. Type 1 diabetes: 
Etiology, immunology, and 
therapeutic strategies. Physiol Rev. 
2011;91(1):79-118.
18. Ludvigsson J et al. GAD treatment 
and insulin secretion in recent-
onset type 1 diabetes. N Engl J Med. 
2008;359(18):1909-20.
19. van Megen KM et al. A future for 
autologous hematopoietic stem cell 
transplantation in type 1 diabetes. 
Front Immunol. 2018;9:690.
20. Snarski E et al. Immunoablation and 
autologous hematopoietic stem cell 
transplantation in the treatment of 
new-onset type 1 diabetes mellitus: 
Long-term observations. Bone 
Marrow Transplant. 2016;51(3):398-
402.
21. Gabbay MA et al. Effect of 
cholecalciferol as adjunctive 
therapy with insulin on protective 
immunologic profile and decline of 
residual beta-cell function in new-
onset type 1 diabetes mellitus. Arch 
Pediatr Adolesc Med. 2012;166:601-7.
22. Mishra A et al. Effect of 6-months' 
vitamin D supplementation on 
residual beta cell function in children 
with type 1 diabetes: A case control 
interventional study. J Pediatr 
Endocrinol Metab. 2016;29(4):395-
400.
23. Xiang H et al. Residual beta-cell 
function predicts clinical response 
after autologous hematopoietic stem 
cell transplantation. Stem Cells Transl 
Med. 2016;5(5):651-7.
24. Benjamin U. Nwosu. Vitamin D and 
residual beta-cell function in type 
1 diabetes (PCR). NCT03046927. 
https://clinicaltrials.gov/ct2/show/
NCT03046927.
25. Lundberg RL et al. Partial clinical 
remission in type 1 diabetes: A 
comparison of the accuracy of total 
daily dose of insulin of <0.3 units/kg/
day to the gold standard insulin-dose 
adjusted hemoglobin A1c of </=9 
for the detection of partial clinical 
remission. J Pediatr Endocrinol 
Metab. 2017;30(8):823-30.
26. Nielens N et al. Integration of routine 
parameters of glycemic variability in 
a simple screening method for partial 
remission in children with type 1 
diabetes. J Diabetes Res. 2018.
27. Scholin A et al. Factors predicting 
clinical remission in adult patients 
with type 1 diabetes. J Intern Med. 
1999;245(2):155-62.
Creative Commons Attribution-Non Commercial 4.0 March 2019  •  EUROPEAN MEDICAL JOURNAL 97
28. Scholin A et al.; Diabetes Incidence 
Study in Sweden. Islet antibodies and 
remaining beta-cell function 8 years 
after diagnosis of diabetes in young 
adults: A prospective follow-up of 
the nationwide Diabetes Incidence 
Study in Sweden. J Intern Med. 
2004;255(3):384-91.
29. Neylon OM et al. Insulin-dose-
adjusted HbA1c-defined partial 
remission phase in a paediatric 
population--When is the honeymoon 
over? Diabet Med. 2013;30(5):627-8.
30. Scholin A et al.; Diabetes Incidence 
Study Group in Sweden (DISS). 
Proinsulin/C-peptide ratio, glucagon 
and remission in new-onset Type 1 
diabetes mellitus in young adults. 
Diabet Med. 2011;28(2):156-61.
31. Willcox A et al. Analysis of islet 
inflammation in human type 
1 diabetes. Clin Exp Immunol. 
2009;155(2):173-81.
32. Meier JJ et al. Postprandial 
suppression of glucagon secretion 
depends on intact pulsatile insulin 
secretion: Further evidence for the 
intraislet insulin hypothesis. Diabetes. 
2006;55(4):1051-6.
33. Alizadeh BZ et al.; DIABMARKER 
Study Group. Association of 
interferon-gamma and interleukin 
10 genotypes and serum levels 
with partial clinical remission in 
type 1 diabetes. Clin Exp Immunol. 
2006;145(3):480-4.
34. Narsale A et al. Human CD4(+) 
CD25(+) CD127(hi) cells and the 
Th1/Th2 phenotype. Clin Immunol. 
2018;188:103-12.
35. Moya R et al. A pilot study showing 
associations between frequency 
of  D4(+) memory cell subsets at 
diagnosis and duration of partial 
remission in type 1 diabetes. Clin 
Immunol. 2016;166-167:72-80.
36. Glisic-Milosavljevic S et al. At-risk 
and recent-onset type 1 diabetic 
subjects have increased apoptosis in 
the CD4+CD25+ T-cell fraction. PLoS 
One. 2007;2(1):e146.
37. Sanda S et al. Islet antigen specific 
IL-10+ immune responses but 
not CD4+CD25+FoxP3+ cells at 
diagnosis predict glycemic control 
in type 1 diabetes. Clin Immunol. 
2008;127(2):138-43.
38. Samandari N et al. Circulating 
microRNA levels predict residual beta 
cell function and glycaemic control in 
children with type 1 diabetes mellitus. 
Diabetologia. 2017;60(2):354-63.
39. Schölin  A et al. Normal weight 
promotes remission and low 
number of islet antibodies 
prolong the duration of remission 
in Type 1 diabetes. Diabet Med. 
2004;21(5):447-55.
40. Redondo MJ et al.; Type 1 Diabetes 
TrialNet Study Group. A type 1 
diabetes genetic risk score predicts 
progression of islet autoimmunity 
and development of type 1 diabetes 
in individuals at risk. Diabetes Care. 
2018;41(9):1887-94.
41. Marino KR et al. A predictive model 
for lack of partial clinical remission in 
new-onset pediatric type 1 diabetes. 
PLoS One. 2017;12(5):e0176860.
42. Pyziak A et al. Markers influencing the 
presence of partial clinical remission 
in patients with newly diagnosed 
type 1 diabetes. J Pediatr Endocrinol 
Metab. 2017;30(11):1147-53.
43. Lombardo F et al. Two-year 
prospective evaluation of the factors 
affecting honeymoon frequency 
and duration in children with insulin 
dependent diabetes mellitus: The 
key-role of age at diagnosis. Diabetes 
Nutr Metab. 2002;15(4):246-51.
44. Bowden SA et al. Young children (<5 
yr) and adolescents (>12 yr) with 
type 1 diabetes mellitus have low 
rate of partial remission: Diabetic 
ketoacidosis is an important risk 
factor. Pediatr Diabetes. 2008;9(3 Pt 
1):197-201.
45. Bizzarri C et al. Clinical presentation 
and autoimmune characteristics of 
very young children at the onset of 
type 1 diabetes mellitus. J Pediatr 
Endocrinol Metab. 2010;23(11):1151-7.
46. Oram RA et al. The majority of 
patients with long-duration type 1 
diabetes are insulin microsecretors 
and have functioning beta cells. 
Diabetologia. 2014;57(1):187-91.
47. Nwosu BU. Comment on Redondo et 
al. Racial/ethnic minority youth with 
recent-onset type 1 diabetes have 
poor prognostic factors. Diabetes 
Care 2018;41:1017-1024. Diabetes Care 
2018;41(7):e123-4.
48. Redondo MJ et al.; Pediatric 
Diabetes Consortium. Racial/
ethnic minority youth with recent-
onset type 1 diabetes have poor 
prognostic factors. Diabetes Care. 
2018;41(5):1017-24.
49. Bergenstal RM et al.; T1D Exchange 
Racial Differences Study Group. 
Racial differences in the relationship 
of glucose concentrations and 
hemoglobin a1c levels. Ann Intern 
Med. 2017;167(2):95-102.
50. Dagogo-Jack S. Pitfalls in the use 
of HbA(1)(c) as a diagnostic test: 
The ethnic conundrum. Nat Rev 
Endocrinol. 2010;6(10):589-93.
51. Kahkoska AR et al. Association of 
race and ethnicity with glycemic 
control and hemoglobin a1c levels 
in youth with type 1 diabetes. JAMA 
Network Open. 2018;1(5):e181851. 
52. Nwosu BU et al. Children with 
type 1 diabetes who experienced 
a honeymoon phase had 
significantly lower LDL cholesterol 
5 years after diagnosis. PLoS One. 
2018;13(5):e0196912.
53. Redondo MJ et al.; Pediatric 
Diabetes Consortium. Response to 
comment on Redondo et al. Racial/
ethnic minority youth with recent-
onset type 1 diabetes have poor 
prognostic factors. Diabetes Care 
2018;41:1017-1024. Diabetes Care. 
2018;41(7):e125-e126. 
54. Muhammad BJ et al. Partial remission 
phase of diabetes in children younger 
than age 10 years. Arch Dis Child. 
1999;80(4):367-9.
55. Ortqvist E et al. Age governs gender-
dependent islet cell autoreactivity 
and predicts the clinical course in 
childhood IDDM. Acta Paediatr. 
1997;86(11):1166-71.
56. Bonfanti R et al. Parameters 
associated with residual insulin 
secretion during the first year of 
disease in children and adolescents 
with type 1 diabetes mellitus. Diabet 
Med. 1998;15(10):844-50.
57. Barrett EJ et al. Diabetic 
microvascular disease: An Endocrine 
Society Scientific Statement. J Clin 
Endocrinol Metab. 2017;102(12):4343-
410.
58. Shah AS et al. Predictors of 
dyslipidemia over time in youth with 
type 1 diabetes: For the SEARCH for 
Diabetes in Youth Study. Diabetes 
Care. 2017;40(4):607-13.
59. Obermannova B et al. HbA1c but not 
diabetes duration predicts increased 
arterial stiffness in adolescents with 
poorly controlled type 1 diabetes. 
Pediatr Diabetes. 2017;18(4):304-10.
60. Katz ML et al. Influence of HbA1c and 
BMI on lipid trajectories in youths and 
young adults with type 1 diabetes. 
Diabetes Care. 2017;40(1):30-7.
61. Bulut T et al. The prevalence of 
dyslipidemia and associated factors 
in children and adolescents with 
type 1 diabetes. J Pediatr Endocrinol 
Metab. 2017;30(2):181-7.
62. Giuffrida FM et al.; Brazilian Type 1 
Diabetes Study Group (BrazDiab1SG). 
Heterogeneous behavior of lipids 
according to HbA1c levels undermines 
the plausibility of metabolic 
syndrome in type 1 diabetes: Data 
from a nationwide multicenter survey. 
Cardiovasc Diabetol. 2012;11:156.
63. Polak M et al. Type 1 diabetic children 
have abnormal lipid profiles during 
pubertal years. Pediatr Diabetes. 
2000;1(2):74-81.
64. Bao W et al. Longitudinal changes in 
cardiovascular risk from childhood 
to young adulthood in offspring of 
parents with coronary artery disease: 
The Bogalusa Heart Study. JAMA. 
1997;278(21):1749-54.
65. Berenson GS et al. Association 
between multiple cardiovascular 
risk factors and atherosclerosis 
in children and young adults. The 
Bogalusa Heart Study. N Engl J Med. 
1998;338(23):1650-6.
66. Nwosu BU et al. Children with 
type 1 diabetes who experienced 
EUROPEAN MEDICAL JOURNAL  •  March 2019 EMJ  EUROPEAN MEDICAL JOURNAL98
a honeymoon phase had 
significantly lower LDL cholesterol 
5 years after diagnosis. PloS One. 
2018;13(5):e0196912.
67. American Diabetes Association. 
Standards of Medical Care in 
Diabetes-2017 Abridged for Primary 
Care Providers. Clin Diabetes. 
2017;35(1):5-26.
68. Donaghue KC et al.; International 
Society for Pediatric and Adolescent 
Diabetes. ISPAD Clinical Practice 
Consensus Guidelines 2014. 
Microvascular and macrovascular 
complications in children and 
adolescents. Pediatr Diabetes. 2014;15 
Suppl 20:257-69.
FOR REPRINT QUERIES PLEASE CONTACT:   +44 (0) 1245 334450
Available now.
EMJ provides influential articles, presentations of 
scientific research and clinical practice, and in-depth 
reviews of international medical congresses.
Subscribe to EMJ Innovations for free.
  E UROPEANMED I CA L- JOURNAL .COM /SUBSCR I B E
